At a glance
Selected small human studies concern sarcoidosis-associated and diabetic neuropathy. Positive symptom and nerve-related measurements remain exploratory, with developer involvement, multiple outcomes and short observation windows. The 2013 corneal nerve-area measurements have a linked arithmetic correction.
Identity & scope
ARA-290 is the experimental peptide code used in the cited clinical studies. Research on a defined study drug does not verify that a supplier product with the same code is analytically or pharmacologically equivalent.
What the research shows
- The 2012 pilot improved a small-fibre symptom score, while pain and fatigue improved similarly in both groups.
- The 2013 study reported symptom, corneal-nerve and selected functional changes in patients with documented nerve-fibre loss.
Critical interpretation
Symptoms and nerve images answer different questions
A symptom scale is directly relevant to experience, while corneal imaging can test a proposed biological effect. Concordance would strengthen a hypothesis, but neither measure should be assumed to validate the other. Our interpretation is that selecting a favourable nerve subgroup after seeing the data is less conclusive than prospectively defining that population and reproducing the finding with a prespecified analysis. [2] [3]
Inspect the corrected measurement before pooling
The nerve-area erratum is material to any quantitative synthesis even if a summary does not quote the old numbers. Area, fibre count and fibre density should remain separate variables with their units and algorithms. Before combining studies, a researcher should determine which measurement was corrected and whether the extracted data reflect it, rather than treating every corneal endpoint as interchangeable. [4] [2]
Small studies cannot settle safety
Short trials may suggest feasibility without estimating uncommon or delayed harms. The diabetes report illustrates why abstract-level reassurance should be checked against the full safety section and participant flow. An event judged unrelated does not prove a cause, while an uncertain attribution does not justify ignoring it. Larger independent trials and longer follow-up are needed for a robust benefit-risk assessment. [1] [3]
Limitations & uncertainties
- Small exploratory trials with several endpoints can overestimate or incompletely characterise effects.
- Results from sarcoidosis-associated neuropathy cannot establish general nerve regeneration or recovery from unrelated injuries.
- Study duration and sample size leave important safety and durability questions; catalogue nasal and vial formulations were not validated.
Open research questions
- Do larger independently replicated trials confirm prespecified benefits?
- How durable are effects on function, symptoms and objective nerve measures?
Selected papers & source records
Download bibliography1. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study (opens in a new tab)
Heij L, Niesters M, Swartjes M, et al. (2012). Molecular Medicine. DOI: 10.2119/molmed.2012.00332 (opens in a new tab) · PMID 23168581
- Design & population
- Exploratory four-week double-blind placebo-controlled study in 22 sarcoidosis patients with neuropathy symptoms.
- What the study found
- Small-fibre symptom scores improved more with ARA-290; pain and fatigue scores improved similarly in both groups.
- Limits on interpretation
- Pilot scale, multiple symptom outcomes and limited duration. The safety observations cannot establish long-term safety.
Original source (opens in a new tab) · Full text at publisher / archive (opens in a new tab)
2. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density (opens in a new tab)
Dahan A, Dunne A, Swartjes M, et al. (2013). Molecular Medicine. DOI: 10.2119/molmed.2013.00122 (opens in a new tab) · PMID 24136731
- Design & population
- Blinded placebo-controlled study in sarcoidosis-associated small-nerve-fibre loss with short treatment and subsequent follow-up.
- What the study found
- Reported improved neuropathic symptoms, corneal nerve-fibre density and selected sensory and exercise measurements.
- Limits on interpretation
- Small disease-specific study with several measures. Nerve-marker changes do not prove general tissue recovery. The corneal nerve-fibre area algorithm was corrected in a 2016 erratum; use corrected values if extracting that endpoint.
Original source (opens in a new tab) · Full text at publisher / archive (opens in a new tab)
3. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes (opens in a new tab)
Brines M, Dunne AN, van Velzen M, et al. (2015). Molecular Medicine. DOI: 10.2119/molmed.2014.00215 (opens in a new tab) · PMID 25387363
- Design & population
- Short phase 2 double-blind placebo-controlled study in type 2 diabetes with painful neuropathy; 49 enrolled, 48 analysed. Published online in 2014, PubMed issue record dated 2015.
- What the study found
- Reported changes in selected glycaemic and neuropathic measures. A corneal-nerve subgroup analysis was post hoc.
- Limits on interpretation
- Small, short, multiple-outcome study with developer involvement. Serious adverse events occurred, including a withdrawal for renal deterioration; causal attribution was not established.
Original source (opens in a new tab) · Full text at publisher / archive (opens in a new tab)
4. Erratum to: ARA 290 Improves Symptoms in Patients with Sarcoidosis-Associated Small Nerve Fiber Loss and Increases Corneal Nerve Fiber Density (opens in a new tab)
Dahan A, Dunne A, Swartjes M, et al. (2016). Molecular Medicine. DOI: 10.2119/molmed.2013.00122.erratum (opens in a new tab) · PMID 28059429
- Design & population
- Publisher erratum correcting the 2013 corneal nerve-fibre area algorithm, not another participant study.
- What the study found
- States that the original area values were too small and provides correction and area-normalisation factors.
- Limits on interpretation
- Do not extract uncorrected absolute nerve-area values from the original paper. Area and nerve-fibre density are distinct measurements.
Original source (opens in a new tab) · Full text at publisher / archive (opens in a new tab)
Search & review scope
Targeted primary-record review using PubMed, PMC and publisher records, starting with existing HeartPep references and selected additional searches.. Checked 9 November 2026.
Two early sarcoidosis trials, a short diabetes-neuropathy trial and the corneal nerve-area erratum. Selected full-text methods, endpoints and safety sections consulted where accessible; no comprehensive neuropathy evidence synthesis.
Selected narrative evidence review, not a systematic search or meta-analysis. Abstract-led unless an individual record is marked full-text. No claim that all studies, registries or unpublished results were searched. Linked notices and targeted correction/retraction searches were checked where accessible. This is not a complete publication-status or raw-data audit; missing search results do not certify that a paper has no updates.
Recorded search terms
- 24136731 ARA-290 sarcoidosis small fiber neuropathy
- "ARA 290 improves symptoms" 2013 Dahan 00122
- "23168581" ARA "10." Heij
- ARA 290 type 2 diabetes neuropathy placebo Brines 2015 trial
- "10.2119/molmed.2013.00122" correction retraction
- "10.2119/molmed.2014.00215" erratum correction
Read the collection’s methods and editorial limits. For formal research, assess and cite the original paper.
Cite this review
HeartPep. ARA-290: literature review. HeartPep literature library. Reviewed 9 November 2026. https://heartpep.com/uk/research/library/ara-290.
HeartPep is the commercial publisher of this secondary summary. It is not a peer-reviewed primary paper. Cite the original studies for their findings.
Buy from HeartPep.com
Laboratory research only. Not for human or veterinary use.